# Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)

Source: https://onco.cc/trials/nct06881784/  
OnCo record `nct06881784` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Daraxonrasib, Docetaxel in non-small-cell lung cancer and small-cell lung cancer, run by Revolution Medicines, Inc., now recruiting.

## Summary

Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301) is a phase 3 interventional study registered as NCT06881784 by Revolution Medicines, Inc., with 590 participants planned, started 2025-05-06 and due to reach its primary completion in 2027-12-01. Interventions recorded: daraxonrasib, docetaxel. Conditions listed: NSCLC (Non-small Cell Lung Cancer), Non-Small Cell Lung Cancer, NSCLC, NSCLC (Non-small Cell Lung Carcinoma). No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06881784
- Phase: 3
- Setting: RASolve 301: Phase 3 Multicenter, Open Label, Randomized Study of RMC-6236 Versus Docetaxel in Patients With Previously Treated Locally Advanced or Metastatic RAS[MUT] NSCLC
- Sponsor: Revolution Medicines, Inc.
- Enrolled: 590

## Sources

- ClinicalTrials.gov NCT06881784: https://clinicaltrials.gov/study/NCT06881784

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [Daraxonrasib](https://onco.cc/drugs/daraxonrasib/), [Docetaxel](https://onco.cc/drugs/docetaxel/)
- companies: [Revolution Medicines](https://onco.cc/companies/revolution-medicines/)

---
JSON: https://onco.cc/api/v1/entities/nct06881784.json